The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients
Chronic Kidney Disease, Anemia, Complication of Peritoneal Dialysis
About this trial
This is an interventional treatment trial for Chronic Kidney Disease focused on measuring Flow mediated dilatation, Brachial artery, Anemia, Chronic kidney disease, Renogen, Erythropoietin Alpha
Eligibility Criteria
Inclusion Criteria:
- Patients aged 18 to 60 years old
- Newly diagnosed ESRD patients started on peritoneal dialysis for less than 3 months not previously on any type of EPO. If previously on a different brand of EPO, patient will have a washout period of 4 weeks.
- Can follow up at NKTI OPD for at least 3 months
- Can take oral iron supplements
Exclusion Criteria:
- Known allergy to EPO
- With severe illness such as congestive heart failure Class III - IV, acute myocardial infarction, infection within 1 month of starting the study or had a severe hepatic disease.
Sites / Locations
- Department of Adult Nephrology; National Kidney and Transplant Institute
Arms of the Study
Arm 1
Experimental
Incident Peritoneal Dialysis
After signing informed consent form, the patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, the dose of Renogen® will be increased to 200 units/kg/week. If there will still be no increase in the Hb or reticulocyte count in the second month, other causes of anemia will be ruled out. If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.